Financial Performance and Subsidiaries Revenue

PERFORMANCE AT A GLANCE Financial Performance (¹) (million) 1400 1200 1000 800 600 400 200 28,117 43.2% 41.6% 22,424 22,247 21,557 20,224 20,438 9,688 9,250 6,962 6,444 6,900 4,608 LLL 7,098 4,409 3,625 1,700 10,402 7,153 0 02-Jul-18 FY 2018 FY 2019 FY 2020 FY 2021 Revenue EBITDA ■PAT NATCO Pharma Stock Performance 02-Jul-19 02-Jul-20 FY numbers have been prepared under Ind AS (1) Represents consolidated gross revenue and includes other income (3)As on June 30,, 2023 02-Jul-21 02-Jul-22 (2) Represents PAT after minority interest FY 2022 Profitability Margins NATCO 34.1% 32.9% 31.0% 29.0% 22.8% 20.5% 17.7% 8.3% 37.0% 25.4% FY 2023 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 EBITDA% PAT% Ownership Structure (3) 50.24% 49.76% 29% 24% 23% 18% Efficiency Ratios 15% 14% 12% 11% 5% 4% 18% 15% ■ Promoter Public FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 No. of fully paid up equity shares held: 17,91,09,870 ROE ROCE 4

View entire presentation